AI chatbot aims to tame diabetes drug side effects

NCT ID NCT07546357

Not yet recruiting Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new AI-powered tool called AIManage that helps doctors and patients manage medications for diabetes and obesity. The tool provides personalized advice on side effects and dose adjustments. The study is in its early stages, with only 16 participants, and is focused on whether people find the tool useful and easy to use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI-driven clinical decision support tool (AIManage)
What this could lead to: If successful, this could lead to a practical AI assistant that helps doctors and patients better manage diabetes and obesity medications, reducing side effects and improving dosing.
What could go wrong: This is a very early, small study (16 participants) focused on gathering feedback on the tool's usability, not on proving it improves health outcomes. The tool may not be widely adopted or effective in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Drug-Related Side Effects and Adverse Reactions Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MEDICATION SIDE EFFECTS OBESITY

Contacts and locations

Locations

NYU Langone Health

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.